RA
ORGO icon

Royce & Associates’s Organogenesis Holdings ORGO Stock Holding History

Royce & Associates’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-17,968
Closed -$38.3K – 950
2023
Q1 		$38.3K Sell
17,968
-1,283
-7% -$3.17K ﹤0.01% 909
2022
Q4 		$51.8K Buy
19,251
+2,565
+15% +$7.48K ﹤0.01% 900
2022
Q3 		$54K Buy
+16,686
New +$75.4K ﹤0.01% 918

Other funds holding ORGO

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates's ORGO Position: Q2 2023 in Review

Royce & Associates sold out of Organogenesis Holdings (ORGO) in Q2 2023, closing a stake of 17,968 shares — an estimated $38.3K sold.

Royce & Associates first reported a position in ORGO in Q3 2022 and held it in 3 quarters. The position peaked at $54K in Q3 2022. 113 funds tracked by Wall St. Rank hold ORGO as of Q2 2023.

  • Royce & Associates reported no remaining Organogenesis Holdings position as of Q2 2023 after selling out during the quarter.
  • Royce & Associates sold 17,968 Organogenesis Holdings shares in Q2 2023, an estimated $38.3K.
  • Royce & Associates first reported a position in Organogenesis Holdings in Q3 2022 and held it in 3 quarters.
  • Royce & Associates's Organogenesis Holdings position peaked at $54K in Q3 2022.
  • 113 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2023.

Based on Royce & Associates's 13F filing for Q2 2023, filed 7 Aug 2023.